# GL Capital

> GL Capital is a VC fund in Shanghai backing Biotechnology and Health Care. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 11
- Last investment: Apr 2023
- Lead investor: 64%
- Last updated: Aug 2026

GL Capital is a VC fund in Shanghai focused on Biotechnology and Health Care. Established in 2010, GL Capital is a Greater China healthcare-focused, value-driven investment management group. Since inception, GL Capital has developed a reputation as the partner-of-choice for leading healthcare companies and demonstrated capability to add value to its portfolio companies.

## Contacts

5 contacts available for GL Capital. Shizune tracks 1 team members at GL Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/gl-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 55% |
| Health Care | 5 | 45% |
| Medical | 4 | 36% |
| Pharmaceutical | 3 | 27% |
| Genetics | 2 | 18% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 5 | 45% |
| Series A | 3 | 27% |
| Series B | 1 | 9% |
| Post-IPO Equity | 1 | 9% |
| Venture - Series Unknown | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 7 | 64% |
| Switzerland | 1 | 9% |
| United States | 1 | 9% |
| United Kingdom | 1 | 9% |
| The Netherlands | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jeffrey Li | Founder, Chairman & Chief Executive Officer | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sangon Biotech | Sangon Biotech Co. (生工生物) is engaged in the research and development of chemical synthesis of DNA.It is a high-tech Sino-foreign joint venture established in 2003. After ten years of development, Sangon has become a professional biotechnology company that integrates research and development. Chemical synthesis DNA earned reputation for Sangonin the global market.In 2006, Sangon invested 50 million to build a manufacturing and industrial base in Songjiang Industrial Park, which has been put into use. Sangon produces various products such as DNA synthesis, DNA sequencing, Gene Synthesis, peptide synthesis, chemical agents, enzymes, molecular biology kit, cultivation medium, lab consumptive material, and miniature instruments. | $290.4M | Venture - Series Unknown | Apr 19, 2023 |  |
| Asia Pacific Medical Group | APMG is an early foreign-funded medical institution that entered the field of medical services in China. |  | Series A | Nov 16, 2022 |  |
| ImmunOs Therapeutics | ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease. | $72.9M | Series B | Jun 07, 2022 |  |
| Nest | Nest Bio is a manufacturer of disposable medical consumables, focusing on the R&D and production of cell culture consumables. |  | Series A | Jun 07, 2022 |  |
| Duoning Biotech | Duoning Biotech is a serum-free medium and technology developer based on international animal cell culture concepts and process development experience. It is committed to the development and production of serum-free media for new animal cells, while providing formula production and technical support for the biopharmaceutical industry. Withancillary services, the products include basic media such as S1, S2, S3, S3-CD and S4, as well as 2×103 feeds and other feed media based on 2×103 feeds; and customized services. |  | Series C | Nov 24, 2021 |  |
| Hzymes Biotechnology | Is a high-tech enterprise focusing on R&D, manufacture, and sales of in vitro diagnostic (IVD) products. | $125.2M | Series C | Nov 10, 2021 |  |
| Tongshu Gene | Tongshu Gene is a high-tech enterprise that focuses on the field of tumor precision medicine. The company provides gene testing services and develops diagnostic molecular pathology projects and ctDNA precision detection systems based on high-throughput gene sequencing technology and biological information analysis to provide clinicians withconsulting services including precision medication, efficacy monitoring, postoperative recurrence monitoring, and risk prediction and early detection. | $78.1M | Series C | Jun 15, 2021 |  |
| New Amsterdam Pharma | NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. | $194.4M | Series A | Jan 14, 2021 |  |
| Huayin Health | Huayin Health is a comprehensive healthcare and medical service group, focuses on providing laboratory and pathological services. | $85M | Series C | Apr 08, 2020 |  |
| Oxford Biodynamics | Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and developmentprocess, improve the success rate of therap. | $12.8M | Post-IPO Equity | Aug 24, 2018 |  |

10 of 11 investments shown.

## Co-investors
- Defu Capital — VC Fund, 2 deals together
- [Everest Venture Capital](https://shizune.co/investors/profile/everest-venture-capital) — VC Fund, 2 deals together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 2 deals together
- [Legend Capital](https://shizune.co/investors/profile/legend-capital) — VC Fund, 2 deals together
- [99Fund](https://shizune.co/investors/profile/99fund) — VC Fund, 1 deal together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does GL Capital invest in?

GL Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series C and Series A stage. Most of the 11 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact GL Capital?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at GL Capital?

The team at GL Capital includes Jeffrey Li (Founder, Chairman & Chief Executive Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co